无容量
免疫疗法
易普利姆玛
彭布罗利珠单抗
医学
结直肠癌
肿瘤科
癌症
黑色素瘤
肾细胞癌
嵌合抗原受体
临床试验
癌症免疫疗法
内科学
免疫学
癌症研究
作者
Wen Zhao,Lujia Jin,Peng Chen,Dingchang Li,Wenxing Gao,Guanglong Dong
出处
期刊:Cancer Letters
[Elsevier]
日期:2022-07-08
卷期号:545: 215816-215816
被引量:53
标识
DOI:10.1016/j.canlet.2022.215816
摘要
Compared with conventional chemotherapy and targeted therapy, immunotherapy has changed the treatment prospects of various solid tumors and has recently become the main treatment method for metastatic or recurrent solid tumors, including malignant melanoma, non-small-cell lung cancer, and renal cell carcinoma. The application of immune checkpoint inhibitor (ICI)-based immunotherapy in patients with colorectal cancer (CRC) has yielded satisfactory results in terms of safety and efficacy, and several immunotherapeutic agents, including pembrolizumab, nivolumab, and ipilimumab, have been approved for the treatment of advanced CRC. The advent of other immunotherapies, such as chimeric antigen receptor-modified T (CAR-T) cells or cancer vaccines, have also contributed to the development of immunotherapy for CRC. Here, we summarize the findings of recent clinical trials on the efficacy of immunotherapy in CRC and briefly describe the mechanisms associated with tumor-intrinsic resistance to ICIs. We then discuss potential biomarkers for predicting the efficacy of immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI